DrugPatentWatch Database Preview
Details for Patent: 6,602,911
Which drugs does patent 6,602,911 protect, and when does it expire?
Patent 6,602,911 protects SAVELLA and is included in one NDA.
This patent has sixteen patent family members in nine countries.
Summary for Patent: 6,602,911
| Title: | Methods of treating fibromyalgia |
| Abstract: | The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed. |
| Inventor(s): | Kranzler; Jay D. (La Jolla, CA), Rao; Srinivas G. (San Diego, CA) |
| Assignee: | Cypress Bioscience, Inc. (San Diego, CA) |
| Application Number: | 10/028,547 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,602,911 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 6,602,911
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan Sales Llc | SAVELLA | milnacipran hydrochloride | TABLET;ORAL | 022256-001 | Jan 14, 2009 | RX | Yes | No | Start Trial | Start Trial | MANAGEMENT OF FIBROMYALGIA (FM) | Start Trial | ||||
| Allergan Sales Llc | SAVELLA | milnacipran hydrochloride | TABLET;ORAL | 022256-002 | Jan 14, 2009 | RX | Yes | No | Start Trial | Start Trial | MANAGEMENT OF FIBROMYALGIA (FM) | Start Trial | ||||
| Allergan Sales Llc | SAVELLA | milnacipran hydrochloride | TABLET;ORAL | 022256-003 | Jan 14, 2009 | RX | Yes | Yes | Start Trial | Start Trial | MANAGEMENT OF FIBROMYALGIA (FM) | Start Trial | ||||
| Allergan Sales Llc | SAVELLA | milnacipran hydrochloride | TABLET;ORAL | 022256-004 | Jan 14, 2009 | RX | Yes | No | Start Trial | Start Trial | MANAGEMENT OF FIBROMYALGIA (FM) | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 6,602,911
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 552856 | Start Trial | |||
| Australia | 2003268020 | Start Trial | |||
| Canada | 2467356 | Start Trial | |||
| Canada | 2493490 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
